Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.37 |
| ▸ | TMPRSS15 | P98073 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 5/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3287771 | 0.80 | HDAC6 (0.54) | MYCHDAC6ALDH1A1KEAP1SMYD3 | |
| SCHEMBL3288664 | 0.78 | HDAC6 (0.49) | MYCHDAC6ALDH1A1KEAP1NAMPT | |
| SCHEMBL28052395 | 0.75 | MYC (0.56) | MYCHDAC6ALDH1A1AKR1C3 | |
| SCHEMBL3287872 | 0.74 | F11 (0.53) | MYCHDAC6ALDH1A1KEAP1NAMPT | |
| SCHEMBL1026202 | 0.73 | NOTUM (0.61) | MYCHDAC6ALDH1A1NAMPTAKR1C3 | |
| SCHEMBL3281075 | 0.72 | HDAC6 (0.51) | MYCHDAC6ALDH1A1KEAP1NAMPT | |
| SCHEMBL4431726 | 0.72 | HDAC6 (0.77) | HDAC6ALDH1A1KEAP1NAMPTPOLB | |
| SCHEMBL17560248 | 0.72 | PRMT5 (0.57) | MYCHDAC6ALDH1A1NAMPTKDM1A | |
| SCHEMBL14101079 | 0.70 | ESR1 (0.70) | MYCHDAC6ALDH1A1PRSS1TMPRSS15 | |
| SCHEMBL27812215 | 0.69 | ALDH1A1 (0.65) | MYCHDAC6ALDH1A1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705017-B2 | Compounds for treatment of neurodegenerative diseases | EN VIVO PHARMACEUTICALS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-20060004041-A1 | Compounds for treatment of neurodegenerative diseases | ENVIVO PHARMACEUTICALS, INC. | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004041-A1 | Compounds for treatment of neurodegenerative diseases | HDAC5, HDAC6, HDAC3 | MYC 4493/4885HDAC6 2/4885ALDH1A1 681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.